RE:Impacted by end of agrements in LATAM- is this only Gilead ?Snowballgrowth wrote: Consolidated, no significant growth
From what I recall - only Gilead.
Also - there will always be quarters where growth stalls/pauses.
What is the next leg of growth? Likely further growth in Exelon to continue.
Singular Genomics is likely at the end of its negative run on our numbers.
I honestly haven't looked at the numbers closely yet - will eventually.
Looks like Endo (Paladin) is taking a 20% haircut on thier sales (last quarter) ... from $23M to $18M USD. Not a good time for this but renewals will be difficult under their present bakruptcy condition. They have lost a product agreement - maybe Plan B ? Wonder if we are interested or will be competitive in bidding. Certainly wouldn't be the first we stole from them (e.g. Trelstar).
---------------
International Pharmaceuticals. The decreases in International Pharmaceuticals revenues for the three and nine months ended September 30, 2022 were primarily attributable to competitive pressures and the expiration of a product agreement.
---------------
Always interesting to see where we go next. Patience.